Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer

  1. Aguilar-Serra, J.
  2. Gimeno-Ballester, V.
  3. Pastor-Clerigues, A.
  4. Milara, J.
  5. Trigo-Vicente, C.
  6. Cortijo, J.
Aldizkaria:
Expert Review of Pharmacoeconomics and Outcomes Research

ISSN: 1744-8379 1473-7167

Argitalpen urtea: 2022

Alea: 22

Zenbakia: 4

Orrialdeak: 637-646

Mota: Artikulua

DOI: 10.1080/14737167.2022.1987220 GOOGLE SCHOLAR